U.S. markets open in 7 hours 27 minutes

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.33000.0000 (0.00%)
At close: 04:00PM EDT
2.3300 0.00 (0.00%)
After hours: 06:26PM EDT

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000

Full Time Employees87

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsCEO & Director1.14MN/A1965
Mr. Jeffrey L. Wade J.D.Pres & CFO718.14kN/A1965
Mr. Brian T. CrumSr. VP, Gen. Counsel & Sec.557.49kN/A1973
Dr. Alan J. Main Ph.D.Exec. VP of Innovation & Chemical Sciences574.2kN/A1954
Dr. Craig B. Granowitz M.D., Ph.D.Sr. VP & Chief Medical Officer450.46kN/A1965
Dr. Robert J. Lefkowitz M.D.Consultant & Independent Director50kN/A1944
Ms. Kristen L. AlexanderVP of Fin. & AccountingN/AN/A1968
Chas SchultzExec. Director of Corp. Communications & Patient AdvocacyN/AN/AN/A
Ms. Wendy E. McDermottVP of HRN/AN/A1971
Dr. Kenneth B. Kassler-Taub M.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1956
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.